179 filings
8-K
NMTRQ
9 Meters Biopharma, Inc.
18 Jul 23
Entry into a Material Definitive Agreement
8:00am
8-K
NMTRQ
9 Meters Biopharma, Inc.
16 Jun 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:26pm
8-K
NMTRQ
9 Meters Biopharma, Inc.
30 May 23
9 Meters Biopharma Announces Management Change and Provides Clinical Update on Vurolenatide in Patients with Short Bowel Syndrome
4:11pm
8-K
NMTRQ
9 Meters Biopharma, Inc.
22 May 23
Other Events
8:05am
8-K
NMTRQ
9 Meters Biopharma, Inc.
19 May 23
Entry into a Material Definitive Agreement
8:02am
8-K
uvffw6pqgwfygr09s 5h
15 May 23
9 Meters Biopharma Provides Business Update and Reports Financial Results for First Quarter 2023
5:16pm
8-K
x7rtnd51 cd7h3l
27 Apr 23
Entry into a Material Definitive Agreement
8:17am
8-K
8vfx3ynumfm5q 7oc9p
6 Apr 23
Entry into a Material Definitive Agreement
4:15pm
8-K
k1dj3
5 Apr 23
9 Meters Biopharma Announces Successful Pre-IND Meeting with FDA Regarding its GIP Antagonist NM-136 for Obesity
8:31am
8-K
rgcghh8 zp8jkq
28 Mar 23
9 Meters Biopharma Provides Business Update and Reports Financial Results for Fourth Quarter and Full Year 2022
8:03am
8-K
qeomt
15 Mar 23
9 Meters Biopharma Announces $5 Million Registered Direct Offering
4:08pm
8-K
pcqiextzzwid6q9z
13 Mar 23
Other Events
2:40pm
8-K
awbw qgvv9rprzr9t
13 Mar 23
Other Events
8:25am
8-K
wx963l q6pxx
13 Jan 23
Entry into a Material Definitive Agreement
9:05am
8-K
zquqwnxyk b09m4hy
29 Nov 22
9 Meters Biopharma Announces Phase 3 Study of Vurolenatide
8:05am
8-K
upy7h5
8 Nov 22
9 Meters Biopharma Provides Business Update and Reports Financial Results for Third Quarter 2022
8:05am
8-K
f8lo1bwl1l1j 4fbbtr
1 Nov 22
Other Events
4:10pm
8-K
al2qnlfl
21 Oct 22
Submission of Matters to a Vote of Security Holders
4:15pm
8-K
f0l396m5vsigio
17 Oct 22
9 Meters Biopharma Announces 1-for-20 Reverse Stock Split
8:41am
8-K
kywn3su8zefa1r
6 Oct 22
Entry into a Material Definitive Agreement
4:15pm